

# UC Berkeley

## UC Berkeley Previously Published Works

### Title

Comparison of Influenza and Coronavirus Disease 2019-Associated Hospitalizations Among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October-April 2017-2021) and COVID-NET (October 2020-September 2021).

### Permalink

<https://escholarship.org/uc/item/7z8200j5>

### Journal

Clinical Infectious Diseases, 76(3)

### Authors

Delahoy, Miranda  
Ujamaa, Dawud  
Taylor, Christopher  
et al.

### Publication Date

2023-02-08

### DOI

10.1093/cid/ciac388

Peer reviewed

1 **Comparison of influenza and COVID-19–associated hospitalizations among children < 18 years old in**  
2 **the United States — FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–**  
3 **September 2021)**

4  
5 Miranda J. Delahoy, PhD<sup>\*1,2,3</sup>; Dawud Ujamaa, MS<sup>\*1,2</sup>; Christopher A. Taylor, PhD<sup>1</sup>; Charisse Cummings,  
6 MPH<sup>1,2</sup>; Onika Anglin, MPH<sup>1</sup>; Rachel Holstein, MPH<sup>1,2</sup>; Jennifer Milucky, MSPH<sup>1</sup>; Alissa O’Halloran,  
7 MSPH<sup>1,2</sup>; Kadam Patel, MPH<sup>1</sup>; Huong Pham, MPH<sup>1</sup>; Michael Whitaker, MPH<sup>1</sup>; Arthur Reingold, MD<sup>4,5</sup>;  
8 Shua J. Chai, MD<sup>4,6</sup>; Nisha B. Alden, MPH<sup>7</sup>; Breanna Kawasaki, MPH<sup>7</sup>; James Meek, MPH<sup>8</sup>; Kimberly  
9 Yousey-Hindes, MPH<sup>8</sup>; Evan J. Anderson, MD<sup>9,10,11</sup>; Kyle P. Openo, DrPH<sup>9,10,11</sup>; Andy Weigel, LMSW<sup>12</sup>;  
10 Kenzie Teno, MPH<sup>12</sup>; Libby Reeg, MPH<sup>13</sup>; Lauren Leegwater, MPH<sup>13</sup>; Ruth Lynfield, MD<sup>14</sup>; Melissa  
11 McMahon, MPH<sup>14</sup>; Susan Ropp, PhD<sup>15</sup>; Dominic Rudin<sup>15</sup>; Alison Muse, MPH<sup>16</sup>; Nancy Spina, MPH<sup>16</sup>;  
12 Nancy M. Bennett, MD<sup>17</sup>; Kevin Popham, MPH<sup>18</sup>; Laurie M. Billing, MPH<sup>19</sup>; Eli Shiltz, MPH<sup>19</sup>; Melissa  
13 Sutton, MD<sup>20</sup>; Ann Thomas, MD<sup>20</sup>; William Schaffner, MD<sup>21</sup>; H. Keipp Talbot, MD<sup>21</sup>; Melanie T. Crossland,  
14 MPH<sup>22</sup>; Keegan McCaffrey<sup>23</sup>; Aron J. Hall, DVM<sup>1</sup>; Erin Burns<sup>2</sup>; Meredith McMorrow, MD<sup>1</sup>; Carrie Reed,  
15 DSc<sup>2</sup>; Fiona P. Havers, MD<sup>1</sup>; Shikha Garg, MD<sup>1,2</sup>

16

17 \*Miranda J. Delahoy and Dawud Ujamaa contributed equally to this manuscript.

18

- 19 1. CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia,  
20 United States
- 21 2. Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for  
22 Disease Control and Prevention, Atlanta, Georgia, United States
- 23 3. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia,  
24 United States
- 25 4. California Emerging Infections Program, Oakland, California, United States
- 26 5. University of California, Berkeley School of Public Health, Berkeley, California, United States
- 27 6. Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta,  
28 Georgia, United States
- 29 7. Colorado Department of Public Health and Environment, Denver, Colorado, United States

- 1 8. Connecticut Emerging Infections Program, Yale School of Public Health, New Haven,
- 2 Connecticut, United States
- 3 9. Emory University School of Medicine, Atlanta, Georgia, United States
- 4 10. Georgia Emerging Infections Program, Georgia Department of Health, Atlanta, Georgia, United
- 5 States
- 6 11. Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States
- 7 12. Iowa Department of Health, Des Moines, Iowa, United States
- 8 13. Michigan Department of Health and Human Services, Lansing, Michigan, United States
- 9 14. Minnesota Department of Health, Saint Paul, Minnesota, United States
- 10 15. New Mexico Emerging Infections Program, New Mexico Department of Health, Santa Fe, New
- 11 Mexico, United States
- 12 16. New York State Department of Health, Albany, New York, United States
- 13 17. University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
- 14 18. Rochester Emerging Infections Program, University of Rochester Medical Center, Rochester,
- 15 New York, United States
- 16 19. Ohio Department of Health, Columbus, Ohio, United States
- 17 20. Public Health Division, Oregon Health Authority, Salem, Oregon, United States
- 18 21. Vanderbilt University Medical Center, Nashville, Tennessee, United States
- 19 22. Salt Lake County Health Department, Salt Lake City, Utah, United States
- 20 23. Utah Department of Health, Salt Lake City, Utah, United States

21  
22 **Corresponding author:** Miranda J. Delahoy, Influenza Division, Centers for Disease Control and  
23 Prevention, 1600 Clifton Rd. MS H24-7, Atlanta, Georgia 30329, United States; email: [vuo0@cdc.gov](mailto:vuo0@cdc.gov).

24  
25 **Alternative corresponding authors:** Shikha Garg, Influenza Division, Centers for Disease Control and  
26 Prevention, 1600 Clifton Rd. MS H24-7, Atlanta, Georgia 30329, United States; email: [izi7@cdc.gov](mailto:izi7@cdc.gov).

27 **Running title:** Pediatric COVID-19 and influenza

28

29

1 **Abstract**

2 **Background:** Influenza virus and SARS-CoV-2 are significant causes of respiratory illness in children.

3 **Methods:** Influenza and COVID-19-associated hospitalizations among children <18 years old were  
4 analyzed from FluSurv-NET and COVID-NET, two population-based surveillance systems with similar  
5 catchment areas and methodology. The annual COVID-19-associated hospitalization rate per 100 000  
6 during the ongoing COVID-19 pandemic (October 1, 2020–September 30, 2021) was compared to  
7 influenza-associated hospitalization rates during the 2017–18 through 2019–20 influenza seasons. In-  
8 hospital outcomes, including intensive care unit (ICU) admission and death, were compared.

9 **Results:** Among children <18 years old, the COVID-19-associated hospitalization rate (48.2) was higher  
10 than influenza-associated hospitalization rates: 2017–18 (33.5), 2018–19 (33.8), and 2019–20 (41.7). The  
11 COVID-19-associated hospitalization rate was higher among adolescents 12–17 years old (COVID-19:  
12 59.9; influenza range: 12.2-14.1), but similar or lower among children 5–11 (COVID-19: 25.0; influenza  
13 range: 24.3-31.7) and 0–4 (COVID-19: 66.8; influenza range: 70.9-91.5) years old. Among children <18  
14 years old, a higher proportion with COVID-19 required ICU admission compared with influenza (26.4% vs  
15 21.6%;  $p < 0.01$ ). Pediatric deaths were uncommon during both COVID-19- and influenza-associated  
16 hospitalizations (0.7% vs 0.5%;  $p = 0.28$ ).

17 **Conclusions:** In the setting of extensive mitigation measures during the COVID-19 pandemic, the annual  
18 COVID-19-associated hospitalization rate during 2020–2021 was higher among adolescents and similar  
19 or lower among children <12 years old compared with influenza during the three seasons before the  
20 COVID-19 pandemic. COVID-19 adds substantially to the existing burden of pediatric hospitalizations and  
21 severe outcomes caused by influenza and other respiratory viruses.

22 **Keywords:** COVID-19; influenza; children; SARS-CoV-2; surveillance

1 **Introduction**

2 Influenza virus and SARS-CoV-2 are significant causes of respiratory illness and can cause severe illness  
3 including death in children [1–5]. Annual influenza vaccination is approved and recommended for  
4 persons  $\geq$  6 months old without contraindications [6], whereas COVID-19 vaccines are currently  
5 authorized or approved for persons  $\geq$  5 years old [7]. Influenza-associated hospitalization rates are  
6 typically highest among adults aged  $\geq$  65 years, followed during some seasons by adults aged 50–64  
7 years and during others by children 0–4 years old [8]. COVID-19-associated hospitalization rates are  
8 similarly higher among adults compared with children [9]. However, data comparing influenza versus  
9 COVID-19-associated hospitalizations among children are limited [10,11]. Such data are useful for  
10 evaluating the impact of mitigation measures and for interpreting disease burden measures, which can  
11 provide useful context to inform COVID-19 vaccine recommendations for children  $<$  5 years old. We  
12 compared hospitalization rates, clinical characteristics, and outcomes among children  $<$  18 years old  
13 hospitalized with influenza or COVID-19 in the United States.

14 **Methods**

15 The Influenza Hospitalization Surveillance Network (FluSurv-NET) [8] and the Coronavirus Disease 2019-  
16 Associated Hospitalization Surveillance Network (COVID-NET) [12,13] conduct population-based  
17 surveillance for laboratory-confirmed influenza- and COVID-19-associated hospitalizations, respectively.  
18 FluSurv-NET was initiated in 2003–04. COVID-NET was initiated in March 2020 using FluSurv-NET  
19 infrastructure [12]. During 2017–18 through 2020–21, FluSurv-NET was conducted in select counties in  
20 14 states participating in the Emerging Infections Program (California, Colorado, Connecticut, Georgia,  
21 Maryland [Baltimore Metropolitan Area], Minnesota, New Mexico, New York, Oregon, and Tennessee)  
22 or the Influenza Hospitalization Surveillance Project (Iowa [2020–21 only], Michigan, Ohio, and Utah),  
23 with a catchment population of approximately 29 million persons. COVID-NET conducts surveillance in

1 all FluSurv-NET counties and state-wide in Maryland, with a catchment population of approximately 32  
2 million persons.

3 FluSurv-NET surveillance is conducted during each influenza season (October 1 through April 30) and  
4 COVID-NET surveillance is conducted year-round [8,13]. A FluSurv-NET or COVID-NET case is defined as a  
5 hospitalized patient who is a resident of the system's catchment area, with a positive influenza (rapid  
6 antigen detection, molecular assay, direct or indirect immunofluorescence assay, or viral culture) or  
7 SARS-CoV-2 (rapid antigen detection or molecular assay) test during or  $\leq$  14 days before hospitalization.

8 Influenza virus or SARS-CoV-2 testing is performed at the discretion of healthcare practitioners or  
9 according to hospital testing practices. Trained surveillance staff identify all catchment area residents  
10 hospitalized with influenza or COVID-19 using laboratory, hospital, and reportable conditions databases.

11 Medical records are abstracted using standardized data collection forms to obtain information on  
12 demographics, clinical characteristics, interventions (invasive mechanical ventilation [IMV] and  
13 extracorporeal membrane oxygenation), and outcomes (intensive care unit [ICU] admission, pneumonia,  
14 and death from any cause) during an influenza- or COVID-19-associated hospitalization.

15 Obesity status was determined using body mass index ( $\geq$  95th percentile for sex and age), ICD-10-CM  
16 discharge diagnosis codes, and problem lists. Acute symptoms at admission were abstracted from  
17 history and physical exam notes; the list of abstracted symptoms varied by surveillance platform and  
18 year. Acute respiratory or febrile symptoms (fever, congestion/runny nose, cough, shortness of breath,  
19 sore throat, upper respiratory illness or influenza-like illness, and wheezing) were abstracted for all  
20 FluSurv-NET seasons and for COVID-NET. Additional symptoms abstracted for FluSurv-NET by season and  
21 for COVID-NET are detailed in Table 1 and Supplementary Table 1.

22 Monthly hospitalization counts were determined for influenza (October–April during the 2017–18  
23 through 2020–21 influenza seasons) and COVID-19 (March 2020–September 2021). Unadjusted

1 influenza and COVID-19-associated hospitalization rates per 100 000 children were calculated by  
2 dividing the total number of hospitalizations by National Center for Health Statistics population  
3 denominators [14]. The COVID-19-associated hospitalization rate was calculated for a 1-year period  
4 (October 1, 2020–September 30, 2021). This annual rate was compared with influenza-associated  
5 hospitalization rates during October 1–April 30 of each of the 2017–18 through 2019–20 influenza  
6 seasons. Influenza occurs seasonally in the United States with low detection during May–September  
7 [15,16], suggesting few influenza-associated hospitalizations are missed outside the October–April  
8 surveillance window. Thus, influenza-associated hospitalization rates during October–April were used to  
9 represent annual rates. Weekly hospitalization rates per 100 000 children were calculated for influenza  
10 (overall and by influenza virus type) and COVID-19.

11 In a *post hoc* analysis, preliminary influenza- and COVID-19-associated hospitalization rates per 100 000  
12 children during the current season, October 1, 2021–April 9, 2022, were calculated.

13 The frequencies of select characteristics and outcomes were calculated for children hospitalized with  
14 influenza (2017–18 through 2019–20 influenza seasons), and COVID-19 (October 1, 2020–September 30,  
15 2021).

16 Children with laboratory-confirmed influenza or COVID-19 may have been hospitalized primarily for  
17 other reasons but found incidentally to have influenza or COVID-19. We conducted sensitivity analyses  
18 to determine whether severe outcomes differed by symptom status (presence of  $\geq 1$  symptom at  
19 admission) for both influenza and COVID-19, and by admission reason for COVID-19 (these data were  
20 not available in FluSurv-NET). For COVID-NET, the primary admission reason was determined from the  
21 chief complaint and history of present illness.

22 *P* values were calculated using Pearson chi-square or Wilcoxon rank sum tests. Statistical significance  
23 was set at  $\alpha = .05$ ; all tests were 2-sided. For hospitalization rates and select analyses of characteristics

1 and outcomes, 95% Confidence Intervals (CI) for binomial proportions were calculated using the  
2 Clopper-Pearson method. Statistical analyses were performed in SAS version 9.4 (SAS Institute).  
3 FluSurv-NET and COVID-NET surveillance activities were reviewed by CDC and conducted consistent with  
4 applicable federal law and CDC policy (e.g., 45 CFR. Part 46.102(l)(2), 21 CFR part 56; 42 USC. §241(d); 5  
5 USC §552a; 44 USC §3501 et seq). Sites participating in FluSurv-NET and COVID-NET obtained human  
6 subjects and ethics approvals from their respective state and local health department and academic  
7 partner Institutional Review Boards as needed.

## 8 **Results**

9 From October 2017 until February 2020, monthly influenza-associated hospitalization counts followed a  
10 typical seasonal pattern (Figure 1); during March–April 2020, influenza-associated hospitalizations  
11 decreased abruptly, coinciding with the March 16, 2020 release of national guidance for slowing the  
12 spread of COVID-19, which included school closures and other mitigation measures [17]. Subsequently,  
13 during October 1, 2020–April 30, 2021, only 9 influenza-associated hospitalizations among children were  
14 reported to FluSurv-NET. Starting in March 2020 (when COVID-NET surveillance was initiated) through  
15 September 2021, COVID-19-associated hospitalizations were identified in children each month (range:  
16 22–470 hospitalizations).

17 Among all children, influenza-associated hospitalization rates during the three seasons before the  
18 COVID-19 pandemic (2017–18 through 2019–20; rate range: 33.5–41.7; 95% CI of highest-burden season  
19 [2019–20]: 40.2–43.3) were lower than one annual COVID-19-associated hospitalization rate observed  
20 during October 2020–September 2021 of the ongoing COVID-19 pandemic (48.2; 95% CI: 46.6–49.8)  
21 (Figure 2; Supplementary Table 2). However, differences were observed by age. Among children 0–4  
22 years old, the influenza-associated hospitalization rate for the 2019–20 season (91.5) was higher than,  
23 and for the 2017–18 season (71.0) and 2018–19 season (70.9) were similar to, the COVID-19-associated



1 hospitalization rate (66.8). Influenza- (2017–18 through 2019–20: 24.3–31.7) and COVID-19- (25.0)  
2 associated hospitalization rates were similar among children 5–11 years old. Among adolescents (12–17  
3 years old), influenza-associated hospitalization rates (2017–18 through 2019–20: 12.2–14.1) were lower  
4 than the COVID-19-associated hospitalization rate (59.9).

5 During October 1, 2021–April 9, 2022, the preliminary COVID-19-associated hospitalization rate among  
6 all children was higher than influenza-associated hospitalization rates during October–April of 2017–18  
7 through 2021–22 and was also higher than the annual COVID-19-associated hospitalization rate during  
8 October 2020–September 2021 (Supplementary Figure 2A). Increases in the COVID-19-associated  
9 hospitalization rate were largely driven by increased rates among infants 0–6 months old  
10 (Supplementary Figure 2B).

11 Weekly influenza-associated hospitalization rates peaked in February during all three seasons before the  
12 COVID-19 pandemic (peak weekly rate range: 2.4–4.0). Rates varied by influenza virus type  
13 (Supplementary Figure 1). The highest weekly rate of COVID-19 during October 2020–September 2021  
14 (1.8) occurred in September 2021.

15 Among 6774 children hospitalized with influenza during 2017–18 through 2019–20 and 3461 children  
16 hospitalized with COVID-19 during October 2020–September 2021, the median age was lower for  
17 influenza (3 years; interquartile range [IQR]: 1–7) than COVID-19 (9 years; IQR: 1–15) (Table 1). Other  
18 demographic characteristics were similar. Overall, 6564 children with influenza (96.9%) and 2760  
19 children with COVID-19 (79.7%) had  $\geq 1$  symptom at admission. A higher proportion of children with  
20 influenza had  $\geq 1$  respiratory or febrile symptom compared to those with COVID-19 (95.6% vs 64.8%).  
21 Other common symptoms among children with influenza versus COVID-19 included nausea/vomiting  
22 (40.1% vs 34.4%), fatigue (29.1% vs 19.0%), and diarrhea (13.8% vs 15.8%) (Supplementary Table 1).

1 Overall, 3774 children hospitalized with influenza (55.7%) and 1857 children hospitalized with COVID-19  
2 (53.7%) had  $\geq 1$  underlying medical condition (Table 2). Asthma/reactive airway disease, neurologic  
3 disorder, and obesity were the most prevalent conditions for influenza and COVID-19. A higher  
4 proportion of children with influenza compared with COVID-19 had asthma (23.6% vs 16.3%) or chronic  
5 lung disease (6.0% vs 3.3%), but lower proportions had diabetes (1.2% vs 3.8%) or obesity (17.5% vs  
6 35.0%).

7 The median hospital length of stay was lower for children with influenza compared with COVID-19 (2 vs  
8 3 days,  $p < 0.01$ ) (Table 2). A higher proportion of children with influenza compared with COVID-19 had  
9 pneumonia (17.8% vs 13.3%;  $p < 0.01$ ), but lower proportions required IMV (5.3% vs 6.2%;  $p = 0.04$ ) or ICU  
10 admission (21.6% vs 26.4%;  $p < 0.01$ ). The proportion of children with influenza vs COVID-19 who died  
11 during hospitalization was similar (0.5% vs 0.7%,  $p = 0.28$ ).

12 In sensitivity analyses, proportions experiencing severe outcomes were similar when examining the  
13 following hospitalization categories: all influenza or COVID-19-associated hospitalizations, influenza or  
14 COVID-19-associated hospitalizations with  $\geq 1$  symptom at admission (96.9% of 6774 influenza  
15 hospitalizations and 79.7% of 3461 COVID-19 hospitalizations), and COVID-19-associated hospitalizations  
16 with COVID-19 as the primary admission reason (74.9% of COVID-19-associated hospitalizations) (Table  
17 3). Among COVID-19-associated hospitalizations, proportions with pneumonia or ICU admission  
18 increased modestly with increasing age when restricted to hospitalizations with  $\geq 1$  symptom at  
19 admission or COVID-19 as the primary admission reason. However, other severe outcomes such as IMV  
20 and in-hospital death were similar across the hospitalization categories.

## 21 **Discussion**

22 Among children  $< 18$  years old, the COVID-19-associated hospitalization rate during one year of the  
23 ongoing COVID-19 pandemic was higher than influenza-associated hospitalization rates during each of

1 the three seasons before the pandemic, with differences observed by age group. Severe outcomes such  
2 as ICU admission, IMV, and in-hospital death were generally similar among children with COVID-19  
3 compared with influenza. Influenza has long been recognized as an important cause of severe  
4 respiratory illness in children in the United States and globally [1,18]. These data add to the growing  
5 literature demonstrating that COVID-19 is also an important cause of severe disease among children.

6 Prevention measures such as physical distancing, mask usage, and virtual learning likely contributed to  
7 historically low levels of influenza circulation during the 2020–21 influenza season in the United States  
8 [19] and globally [20]. The influenza- and COVID-19-associated hospitalization rates among children  
9 during 2020–21 would likely have been higher without mitigation measures. While influenza activity  
10 typically displays a seasonal pattern, peaking during December–March in the northern hemisphere  
11 [15,19], COVID-19-associated hospitalizations occurred throughout 2020–2021 and no distinct  
12 seasonality can yet be distinguished. During the 2009 influenza A H1N1 pandemic (April 2009–April  
13 2010), the H1N1pdm09 virus similarly circulated without distinct seasonality, resulting in spring and fall  
14 activity waves. Notably, H1N1pdm09-associated hospitalization and death rates were highest among  
15 children and younger adults [21]. In subsequent seasons, H1N1pdm09 displayed a typical seasonal  
16 circulation pattern, with decreasing pediatric burden as population immunity levels increased. Given the  
17 relatively condensed annual period during which seasonal influenza viruses circulate, peak weekly  
18 hospitalization rates were higher for influenza during 2017–2020 compared with COVID-19 during  
19 October 2020–September 2021, despite similar annual hospitalization rates. Co-circulation of influenza  
20 and SARS-CoV-2, along with other respiratory viruses, could exacerbate winter surges in pediatric  
21 hospitalizations, posing challenges to healthcare capacity [22,23].

22 While >95% of hospitalized children with influenza had a respiratory or febrile symptom, approximately  
23 one-third of children with COVID-19 did not, and overall, one in five children with COVID-19 did not have  
24 any symptoms at admission. Large proportions of children with influenza or COVID-19 had non-

1 respiratory symptoms, highlighting a range of symptom presentations among children hospitalized with  
2 influenza and COVID-19. Relying on respiratory or febrile symptoms alone could result in missed  
3 opportunities to detect influenza or SARS-COV-2 infections. Respiratory virus testing can help distinguish  
4 between these viruses and guide treatment and infection prevention decisions [24–26]. There were also  
5 differences in the prevalence of underlying conditions among children with influenza versus COVID-19,  
6 which may in part be driven by differences in median age. The prevalence of obesity was approximately  
7 double among children with COVID-19 compared with influenza. Notably, the proportion of children  
8 with COVID-19 who were obese (35%) was similar to findings from another study of hospitalized  
9 children with COVID-19 (32%) [27] and higher than the national obesity prevalence among persons 2–  
10 19 years old (22% in 2020) [28].

11 Our analysis and others demonstrate that both influenza and COVID-19 can cause severe disease in  
12 children [4,5]. Among hospitalized children, 22% with influenza and 26% with COVID-19 required ICU  
13 admission, and 5% with influenza and 6% with COVID-19 required IMV. Proportions experiencing severe  
14 outcomes were generally similar when restricting to those with  $\geq 1$  symptom of influenza or COVID-19 at  
15 admission. Another analysis of COVID-19 hospitalizations among children < 18 years old during July–  
16 August 2021, when the B.1.617.2 (Delta) variant of SARS-CoV-2 was predominant, showed similar  
17 findings with 29.5% requiring ICU admission and 7.9% requiring IMV [27]. Data on COVID-19 treatment  
18 in children are limited, but treatment may be indicated for hospitalized children who have an emergent  
19 or increasing need for supplemental oxygen [26]. To decrease the risk of severe complications, early  
20 antiviral treatment is recommended for children with suspected influenza who are hospitalized or at  
21 higher risk for influenza-associated complications, including children <5 years old and those with  
22 underlying medical conditions [29].

23 Influenza vaccines are safe and effective at preventing hospitalizations, and were available to children  
24  $\geq 6$  months old during all seasons included in this analysis [6,30]. Based on national survey data,

1 influenza vaccination coverage estimates among children  $\geq 6$  months old ranged from 51–63% during  
2 the 2012–13 to 2018–19 seasons [31]. During 2019–20, influenza vaccination averted an estimated  
3 13,798 hospitalizations among children  $\geq 6$  months old [30]. Adolescents were the only children eligible  
4 to receive COVID-19 vaccination for a portion of the time-period covered in this analysis: approvals  
5 differed over time by age (12–15 and 16–17 years) [7]. As of September 30, 2021, 47% of U.S.  
6 adolescents were considered up to date with all recommended COVID-19 doses [32]. COVID-19 vaccines  
7 are both safe and effective at preventing hospitalizations among adolescents and children 5–11 years  
8 old [33–36]. Increased COVID-19 vaccination coverage among children following the emergency use  
9 authorization for COVID-19 vaccines in children 5–11 years old in October 2021 may contribute to  
10 differences in the relative rates of pediatric COVID-19 vs influenza-associated hospitalizations over time.

11 Several limitations should be considered. First, FluSurv-NET and COVID-NET cases may have been  
12 hospitalized for reasons other than influenza or COVID-19 [2]. This may have been more common for  
13 COVID-19 due to SARS-CoV-2 screening practices, which were universal among hospitalized patients at  
14 some facilities during certain time periods. While influenza or COVID-19 may not have been the primary  
15 reason for admission for all hospitalizations, such cases were included in rate calculations because use of  
16 a standard and consistent surveillance case definition allows for robust monitoring of trends over time.

17 Among cases with influenza or SARS-CoV-2 incidentally identified, it is unclear what impact the infection  
18 had on the decision to hospitalize a patient, the hospitalization course, or in-hospital outcomes. In  
19 sensitivity analyses limited to hospitalizations with  $\geq 1$  symptom at admission or COVID-19 as the primary  
20 reason for admission, proportions of children with severe outcomes were similar to proportions when  
21 all hospitalizations were included. Second, COVID-19- and influenza-associated hospitalizations might  
22 have been missed because case identification was reliant on clinician-directed or facility-based testing  
23 practices and test availability. Under-detection of influenza was likely greater than COVID-19 due to  
24 under-utilization of seasonal influenza testing [30]. Third, the impact of extensive mitigation measures

1 during the COVID-19 pandemic, and differential availability of COVID-19 vaccines by age group and time-  
2 period could not be measured, and likely affects the comparison of influenza versus COVID-19-  
3 associated hospitalization rates. Fourth, only deaths occurring during hospitalizations were captured,  
4 which may miss out-of-hospital deaths associated with influenza or COVID-19 [37]. Fifth, the FluSurv-  
5 NET and COVID-NET catchment areas include approximately 9–10% of the U.S. population and findings  
6 may not be generalizable to the entire country. Last, this analysis assessed COVID-19-associated  
7 hospitalization rates during a single year of the ongoing COVID-19 pandemic and did not capture rate  
8 fluctuations that have occurred due to the changing epidemiology of SARS-CoV-2, including the  
9 emergence of variants of concern.

10 The omicron variant of SARS-CoV-2 emerged rapidly during December 2021 and resulted in a peak  
11 COVID-19 weekly hospitalization rate approximately five times as high as the peak hospitalization rate  
12 during the period of Delta variant predominance among children 0–4 years old, a group not yet eligible  
13 for COVID-19 vaccination [38]. Indeed, in a *post hoc* analysis that included months during which the  
14 omicron variant was predominant in the United States, preliminary COVID-19–associated hospitalization  
15 rates among children during October 2021–April 2022 were higher than COVID-19-associated  
16 hospitalization rates observed during October 2020–September 2021 and influenza-associated  
17 hospitalization rates observed during the 2017–18 through 2021–22 seasons.

18 Influenza and SARS-CoV-2 are important causes of severe disease among children. Vaccines can help  
19 prevent illness and attenuate disease severity for both influenza and COVID-19. Prevention and  
20 mitigation measures, including vaccination of all eligible persons, are crucial to protect children,  
21 including those who are not yet eligible for or are too young for vaccination. Without such measures, co-  
22 circulation of influenza virus and SARS-CoV-2, along with other respiratory viruses, could exacerbate  
23 hospitalization surges and overwhelm healthcare capacity, particularly during winter months.

1 **Notes**

2 **Acknowledgements:** Gretchen Rothrock, Jeremy Roland, Joelle Nadle, Pam Kirley (California Emerging  
3 Infections Program); Isaac Armistead, Sarah McLafferty (Colorado Department of Public Health and  
4 Environment); Adam Misiorski, Amber Maslar, Carol Lyons, Daewi Kim, Maria Correa, Paula Clogher,  
5 Tessa Carter (Connecticut Emerging Infections Program, Yale School of Public Health); Allison Roebing,  
6 Annabel Patterson, Asmit Joseph, Chandler Surell, Emily Fawcett, Grayson Kallas, Jana Manning,  
7 Jeremiah Williams, Katelyn Ward, Marina Bruck, Rayna Ceaser, Siyeh Gretzinger, Stephanie Lehman,  
8 Taylor Eisenstein (Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta  
9 Veterans Affairs Medical Center); Suzanne Segler (Division of Infectious Diseases, Emory University  
10 School of Medicine, Georgia Emerging Infections Program, Georgia Department of Public Health); Alicia  
11 Brooks, Cindy Zerlaut, David Blythe, Elisabeth Vaeth (Maryland Department of Health); Michelle Wilson,  
12 Rachel Park (Maryland Emerging Infections Program, The Johns Hopkins Bloomberg School of Public  
13 Health); Alexander Kohrman, Chloe Brown, Jim Collins, Justin Henderson, Shannon Johnson, Sierra  
14 Peguies-Khan, Sue Kim, Val Tellez Nunez (Michigan Department of Health and Human Services);  
15 Alexandra Warzecha, Alison Babb, Amanda Gordon, Austin Bell, Claire Henrichsen, Cynthia Kenyon,  
16 Elizabeth Corey, Emily Holodnick, Emma Contestabile, Erica Bye, Grace Hernandez, Jackie Johnson, Jade  
17 Van Kley, Jennifer Gilbertson, Jill Reaney, Kathryn Como-Sabeti, Kayla Bilski, Kelli Aarstad, Kieu My  
18 Phipps, Lisa Nguyen, Natalie Bullis, Richie Xu, Samantha Siebman (Minnesota Department of Health);  
19 Chelsea McMullen, Emily Hancock, Jasmyn Sanchez, Kathy Angeles, Mayvilynne Poblete, Melissa  
20 Christian, Melissa Judson, Nancy Eisenberg, Sarah Khanlian, Sarah Lathrop, Sarah Shrum Davis, Sunshine  
21 Martinez, Wickliffe Omondi, Yadira Salazar-Sanchez, Yassir Talha (New Mexico Emerging Infections  
22 Program); Murtada Khalifa (CDC Foundation, New Mexico Department of Health); Cory Cline, Daniel  
23 Sosin (New Mexico Department of Health); Adam Rowe, Grant Barney, Kerianne Engesser, Suzanne  
24 McGuire (New York State Department of Health); Christina Felsen, Christine Long, Maria Gaitán,

1 RaeAnne Kurtz, Sophrena Bushey, Thomas Peer, Virginia Cafferky (University of Rochester School of  
2 Medicine and Dentistry); Ann Salvator, Julie Freshwater (Ohio Department of Health); Ama Owusu-  
3 Dommey, Nasreen Abdullah, Nicole West, Sam Hawkins (Public Health Division, Oregon Health  
4 Authority); Anise Elie, Bentley Akoko, Danielle Ndi, John Ujwok, Karen Leib, Kathy Billings, Katie Dyer,  
5 Manideepthi Pemmaraju, Terri McMinn, Tiffanie Markus, Victoria Umutoni (Vanderbilt University  
6 Medical Center); Amanda Carter, Andrea George, Andrea Price, Andrew Haraghey, Ashley Swain, Caitlin  
7 Shaw, Ian Buchta, Jake Ortega, Laine McCullough, Mary Hill, Ryan Chatelian, Tyler Riedesel (Salt Lake  
8 County Health Department); Sonja Nti-Berko, Alvin Shultz (Emerging Infections Program); Mimi Puckett  
9 (Council of State and Territorial Epidemiologists).

10 **Disclaimer:** The conclusions, findings, and opinions expressed by the authors do not necessarily reflect  
11 the official position of the United States Department of Health and Human Services, the United States  
12 Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated  
13 institutions.

14 **Funding:** This work was supported by the Centers of Disease Control and Prevention through an  
15 Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State  
16 and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00). Ms. Leegwater  
17 reports grants from Michigan Department of Health and Human Services, during the conduct of the  
18 study. Ms. Reeg reports CSTE Federal Grant from Michigan Department of Health and Human Services,  
19 during the conduct of the study. Mr. Shiltz and Ms. Billing report grants from Council for State and  
20 Territorial Epidemiologists (CSTE), for the population-based Influenza Hospitalization Surveillance  
21 Project (IHSP) and COVID-Net activities (funded personnel and equipment for data collection activities)  
22 during the conduct of the study.

23 **Potential conflicts of interest:** Dr. Evan Anderson reports grants from Pfizer, grants from Merck, grants  
24 from PaxVax, grants from Micron, grants from Sanofi-Pasteur, grants from Janssen, grants from



1 MedImmune, grants from GlaxoSmithKline (all for clinical trials); personal fees from Sanofi-Pasteur,  
2 personal fees from Pfizer, personal fees from Medscape, personal fees from Kentucky Bioprocessing,  
3 Inc, personal fees from Sanofi-Pasteur, and personal fees from Janssen (all for consulting); and  
4 participation on a personal fees for participating on a Data safety monitoring board for Kentucky  
5 Bioprocessing, Inc and Sanofi-Pasteur outside the submitted work. His institution has also received  
6 funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines, unrelated to this  
7 work. Dr. William Schaffner reports personal fees from VBI Vaccines, outside the submitted work. Ms.  
8 Nisha Alden reports an EIP cooperative agreement from the CDC outside the submitted work. Ms. Teno  
9 reports grants from CDC/CSTE related to flu surveillance activities unrelated to this work. Mr. Weigel  
10 reports multiple grants from CDC/CSTE for flu surveillance (e.g., Youth in Agriculture, Enhancing Laboratory  
11 Capacity) outside the submitted work. Dr. Lynfield reports a position as an associate editor of Red Book  
12 (American Academy of Pediatrics Report of the Committee on Infectious Diseases). Mr. Shiltz reports grants  
13 from Council for State and Territorial Epidemiologists (CSTE), for the population-based Influenza  
14 Hospitalization Surveillance Project (IHSP) and COVID-Net activities (funded personnel and equipment  
15 for data collection activities) unrelated to this work. Ms. Billing reports receipt of Epidemiology and  
16 Laboratory Capacity (ELC) and Immunizations and Vaccines for Children (VFC) grant funding from CDC to  
17 support vaccine preventable disease epidemiology staffing, outside of the submitted work.

18

## 1 References

- 2 1. Doyle JD, Campbell AP. Pediatric influenza and illness severity: what is known and what questions  
3 remain? *Curr Opin Pediatr* **2019**; 31:119–126.
- 4 2. Havers FP, Whitaker M, Self JL, et al. Hospitalization of Adolescents Aged 12–17 Years with  
5 Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021. *MMWR*  
6 *Morb Mortal Wkly Rep* **2021**; 70:851–857.
- 7 3. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations Associated with COVID-19 Among  
8 Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021. *MMWR Morb*  
9 *Mortal Wkly Rep* **2021**; 70:1255–1260.
- 10 4. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–Associated Deaths Among Persons Aged <21  
11 Years — United States, February 12–July 31, 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:1324–  
12 1329.
- 13 5. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-Associated Pediatric Deaths in the  
14 United States, 2010–2016. *Pediatrics* **2018**; 141:e20172918.
- 15 6. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with  
16 Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States,  
17 2021–22 Influenza Season. *MMWR Recomm Rep* **2021**; 70:1–28.
- 18 7. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization Practices’  
19 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years  
20 — United States, November 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1579–1583.
- 21 8. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory  
22 Diseases (NCIRD). Influenza Hospitalization Surveillance Network (FluSurv-NET). 2021. Available at:  
23 <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm>. Accessed 8 December  
24 2021.
- 25 9. Centers for Disease Control and Prevention. COVID-NET: A Weekly Summary of U.S. COVID-19  
26 Hospitalization Data. 2021. Available at:  
27 [https://gis.cdc.gov/grasp/COVIDNet/COVID19\\_5.html#virusTypeDiv](https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html#virusTypeDiv). Accessed 29 December 2021.
- 28 10. Song X, Delaney M, Shah RK, Campos JM, Wessel DL, DeBiasi RL. Comparison of Clinical Features of  
29 COVID-19 vs Seasonal Influenza A and B in US Children. *JAMA Netw Open* **2020**; 3:e2020495.
- 30 11. Kanthimathinathan HK, Buckley H, Lamming C, et al. Characteristics of Severe Acute Respiratory  
31 Syndrome Coronavirus-2 Infection and Comparison With Influenza in Children Admitted to U.K.  
32 PICUs. *Crit Care Explor* **2021**; 3:e0362.
- 33 12. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized  
34 with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020.  
35 *MMWR Morb Mortal Wkly Rep* **2020**; 69:458–464.

- 1 13. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.  
2 Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET).  
3 2021. Available at: [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html)  
4 [methods.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html). Accessed 8 December 2021.
- 5 14. National Center for Health Statistics. Vintage 2020 postcensal estimates of the resident population  
6 of the United States (April 1, 2010, July 1, 2010-July 1, 2020), by year, county, single-year of age (0,  
7 1, 2, .., 85 years and over), bridged race, Hispanic origin, and sex. Prepared under a collaborative  
8 arrangement with the U.S. Census Bureau. 2021; Available at:  
9 [https://www.cdc.gov/nchs/nvss/bridged\\_race.htm](https://www.cdc.gov/nchs/nvss/bridged_race.htm).
- 10 15. Thompson WW. Influenza-Associated Hospitalizations in the United States. *JAMA* **2004**; 292:1333.
- 11 16. Centers for Disease Control and Prevention. FLUVIEW interactive: Age Group Distribution of  
12 Influenza Positive Specimens Reported by Public Health Laboratories, National Summary, 2018-19  
13 Influenza Season. Available at: [https://gis.cdc.gov/grasp/fluview/flu\\_by\\_age\\_virus.html](https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html). Accessed  
14 13 December 2021.
- 15 17. Lasry A, Kidder D, Hast M, et al. Timing of Community Mitigation and Changes in Reported COVID-19  
16 and Community Mobility — Four U.S. Metropolitan Areas, February 26–April 1, 2020. *MMWR Morb*  
17 *Mortal Wkly Rep* **2020**; 69:451–457.
- 18 18. Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections associated with seasonal  
19 influenza in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob*  
20 *Health* **2020**; 8:e497–e510.
- 21 19. Olsen SJ, Winn AK, Budd AP, et al. Changes in Influenza and Other Respiratory Virus Activity During  
22 the COVID-19 Pandemic — United States, 2020–2021. *MMWR Morb Mortal Wkly Rep* **2021**;  
23 70:1013–1019.
- 24 20. Davis WW, Mott JA, Olsen SJ. The role of non-pharmaceutical interventions on influenza circulation  
25 during the COVID-19 pandemic in nine tropical Asian countries. *Influenza Other Respir Viruses* **2022**;  
26 :irv.12953.
- 27 21. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the Burden of 2009 Pandemic Influenza A  
28 (H1N1) in the United States (April 2009–April 2010). *Clin Infect Dis* **2011**; 52:S75–S82.
- 29 22. Murray CJL, Piot P. The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a  
30 Recurrent Seasonal Infection? *JAMA* **2021**; 325:1249.
- 31 23. French G, Hulse M, Nguyen D, et al. Impact of Hospital Strain on Excess Deaths During the COVID-19  
32 Pandemic — United States, July 2020–July 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1613–  
33 1616.
- 34 24. Centers for Disease Control and Prevention. Information for Clinicians on Influenza Virus Testing.  
35 2020. Available at:  
36 [https://www.cdc.gov/flu/professionals/diagnosis/index.htm?web=1&wdLOR=cFFE0C578-9F2C-](https://www.cdc.gov/flu/professionals/diagnosis/index.htm?web=1&wdLOR=cFFE0C578-9F2C-41BB-B251-6F32376C84C3)  
37 [41BB-B251-6F32376C84C3](https://www.cdc.gov/flu/professionals/diagnosis/index.htm?web=1&wdLOR=cFFE0C578-9F2C-41BB-B251-6F32376C84C3). Accessed 10 January 2022.

- 1 25. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19). 2021.  
2 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>. Accessed 10  
3 January 2022.
- 4 26. National Institutes of Health. COVID-19 Treatment Guidelines: Special Considerations in Children.  
5 2021. Available at: <https://www.covid19treatmentguidelines.nih.gov/special-populations/children/>.  
6 Accessed 10 January 2022.
- 7 27. Wanga V, Gerdes ME, Shi DS, et al. Characteristics and Clinical Outcomes of Children and  
8 Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August  
9 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1766–1772.
- 10 28. Lange SJ, Kompaniyets L, Freedman DS, et al. Longitudinal Trends in Body Mass Index Before and  
11 During the COVID-19 Pandemic Among Persons Aged 2–19 Years — United States, 2018–2020.  
12 *MMWR Morb Mortal Wkly Rep* **2021**; 70:1278–1283.
- 13 29. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians.  
14 2021. Available at: <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>.  
15 Accessed 21 November 2021.
- 16 30. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory  
17 Diseases. Estimated Influenza Illnesses, Medical visits, and Hospitalizations Averted by Vaccination  
18 in the United States — 2019–2020 Influenza Season. 2020. Available at:  
19 [https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm?web=1&wdLOR=c2BA5C196-0402-](https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm?web=1&wdLOR=c2BA5C196-0402-4343-BBD1-97BDDEEE1169)  
20 [4343-BBD1-97BDDEEE1169](https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm?web=1&wdLOR=c2BA5C196-0402-4343-BBD1-97BDDEEE1169). Accessed 6 August 2021.
- 21 31. Santibanez TA, Srivastav A, Zhai Y, Singleton JA. Trends in Childhood Influenza Vaccination Coverage,  
22 United States, 2012–2019. *Public Health Rep* **2020**; 135:640–649.
- 23 32. Centers for Disease Control and Prevention. COVID-19 Vaccination and Case Trends by Age Group,  
24 United States. 2021. Available at: [https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-Case-Trends-by-Age-Group-/gxj9-t96f)  
25 [Case-Trends-by-Age-Group-/gxj9-t96f](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-Case-Trends-by-Age-Group-/gxj9-t96f). Accessed 27 December 2021.
- 26 33. Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United  
27 States, December 14, 2020–July 16, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1053–1058.
- 28 34. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA  
29 Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18  
30 Years — United States, July–December 2021. *MMWR Morb Mortal Wkly Rep* **2022**; 71:52–58.
- 31 35. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 Vaccine against Critical  
32 Covid-19 in Adolescents. *N Engl J Med* **2022**; :NEJMoa2117995.
- 33 36. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5  
34 to 11 Years of Age. *N Engl J Med* **2022**; 386:35–46.
- 35 37. Bhat N, Wright JG, Broder KR, et al. Influenza-Associated Deaths among Children in the United  
36 States, 2003–2004. *N Engl J Med* **2005**; 353:2559–2567.
- 37 38. Marks KJ, Whitaker M, Anglin O, et al. Hospitalizations of Children and Adolescents with Laboratory-  
38 Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022. *MMWR Morb Mortal Wkly*  
39 *Rep* **2022**; 71:271–278.

1 **Table 1. Demographic and clinical characteristics of children <18 years old hospitalized with influenza or COVID-19 – FluSurv-NET<sup>1</sup>**  
 2 **and COVID-NET<sup>2</sup>**

	FluSurv-NET			COVID-NET			FluSurv-NET	COVID-NET
	0–4 years	5–11 years	12–17 years	0–4 years	5–11 years	12–17 years	0–17 years	0–17 years
	(N = 3906)	(N = 2013)	(N = 855)	(N = 1293)	(N = 698)	(N = 1470)	(N = 6774)	(N = 3461)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
<b>Age (median, IQR)</b>	1 (0.6–2)	7 (6–9)	14 (13–16)	1 (0.1–2)	8 (6–10)	15 (14–17)	3 (1–7)	9 (1–15)
<b>Sex</b>								
Male	2231 (57.1)	1166 (57.9)	419 (49.0)	694 (53.7)	379 (54.3)	625 (42.5)	3816 (56.3)	1698 (49.1)
Female	1674 (42.9)	847 (42.1)	436 (51.0)	599 (46.3)	319 (45.7)	845 (57.5)	2957 (43.7)	1763 (50.9)
<b>Race/Ethnicity<sup>3</sup></b>								
AI/AN, NH	61 (1.6)	20 (1.0)	11 (1.3)	15 (1.2)	7 (1.0)	18 (1.2)	92 (1.4)	40 (1.2)
Asian/PI, NH	267 (6.8)	93 (4.6)	46 (5.4)	76 (5.9)	28 (4.0)	51 (3.5)	406 (6.0)	155 (4.5)
Black, NH	1065 (27.3)	575 (28.6)	216 (25.3)	394 (30.5)	258 (37.0)	482 (32.8)	1856 (27.4)	1134 (32.8)
Hispanic	1022 (26.2)	445 (22.1)	195 (22.8)	350 (27.1)	186 (26.6)	407 (27.7)	1662 (24.5)	943 (27.2)
White, NH	1155 (29.6)	748 (37.2)	333 (38.9)	362 (28.0)	188 (26.9)	436 (29.7)	2236 (33.0)	986 (28.5)
<b>Insurance status</b>								
Private Insurance	1459 (37.4)	933 (46.3)	380 (44.4)	569 (44.0)	271 (38.8)	626 (42.6)	2772 (40.9)	1466 (42.4)
Federal insurance	2588 (66.3)	1212 (60.2)	513 (60.0)	791 (61.2)	460 (65.9)	908 (61.8)	4313 (63.7)	2159 (62.4)
Other Insurance	45 (1.2)	15 (0.7)	5 (0.6)	37 (2.9)	29 (4.2)	42 (2.9)	65 (1.0)	108 (3.1)
Uninsured	79 (2.0)	49 (2.4)	19 (2.2)	47 (3.6)	10 (1.4)	50 (3.4)	147 (2.2)	107 (3.1)
<b>Symptoms</b>								
Symptom onset to admission (days: median, IQR)	3 (1–5)	3 (1–5)	2 (1–4)	2 (1–4)	3 (1–5)	4 (2–7)	3 (1–5)	3 (1–6)
Any Symptom(s)	3810 (97.5)	1948 (96.8)	806 (94.3)	1104 (85.4)	596 (85.4)	1060 (72.1)	6564 (96.9)	2760 (79.7)
Fever	3364 (86.1)	1705 (84.7)	655 (76.6)	781 (60.4)	380 (54.4)	531 (36.1)	5724 (84.5)	1692 (48.9)
Congestion	2693 (68.9)	1101 (54.7)	404 (47.3)	583 (45.1)	149 (21.3)	267 (18.2)	4198 (62.0)	999 (28.9)
Cough	3129 (80.1)	1561 (77.5)	626 (73.2)	531 (41.1)	247 (35.4)	475 (32.3)	5316 (78.5)	1253 (36.2)
Shortness of breath	1694 (43.4)	745 (37.0)	316 (37.0)	325 (25.1)	137 (19.6)	444 (30.2)	2755 (40.7)	906 (26.2)
Sore throat <sup>4</sup>	92 (10.0)	396 (19.7)	283 (33.1)	18 (9.6)	103 (14.8)	231 (15.7)	771 (20.4)	352 (14.9)

Upper respiratory illness <sup>5</sup>	591 (15.1)	277 (13.8)	139 (16.3)	85 (6.6)	11 (1.6)	35 (2.4)	1007 (14.9)	131 (3.8)
Wheezing	661 (16.9)	346 (17.2)	132 (15.4)	110 (8.5)	47 (6.7)	47 (3.2)	1139 (16.8)	204 (5.9)
Any febrile or respiratory symptom	3770 (96.5)	1924 (95.6)	780 (91.2)	989 (76.5)	483 (69.2)	769 (52.3)	6474 (95.6)	2241 (64.8)
Altered mental state/confusion	133 (3.4)	121 (6.0)	68 (8.0)	35 (2.7)	46 (6.6)	75 (5.1)	322 (4.8)	156 (4.5)
Seizure	330 (8.4)	123 (6.1)	34 (4.0)	55 (4.3)	43 (6.2)	31 (2.1)	487 (7.2)	129 (3.7)
Other symptom(s) <sup>6</sup>	836 (66.8)	490 (79.9)	257 (83.4)	818 (63.3)	490 (70.2)	922 (62.7)	1583 (72.9)	2230 (64.4)
No Symptoms	96 (2.5)	65 (3.2)	49 (5.7)	189 (14.6)	102 (14.6)	410 (27.9)	210 (3.1)	701 (20.3)

1 FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network; IQR = interquartile range

1. FluSurv-NET data include the 2017–2018, 2018–2019, and 2019–2020 seasons. Surveillance is conducted during October 1–April 30 each season. The FluSurv-NET catchment area includes California, Colorado, Connecticut, Georgia, Maryland (Baltimore Metropolitan Area), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. Detailed clinical data on hospitalized cases from Maryland were unavailable for the 2019–20 influenza season and were not included.

2. COVID-NET data during October 1, 2020–September 30, 2021 are included. The COVID-NET catchment area includes California, Colorado, Connecticut, Georgia, Iowa, Maryland (entire state), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

3. NH = Non-Hispanic, AI = American Indian, AN = Alaska Native; Asian race includes Pacific Islander.

4. Data on sore throat were collected for children of all ages but reported only among children ages  $\geq 3$  years (for FluSurv-NET: N = 920 children ages 3–4 and N = 3788 ages 3–17 years; for COVID-NET: N = 188 ages 3–4 and N = 2356 ages 3–17 years).

5. Upper respiratory illness was included as a symptom if there was a note in the medical chart referring to a patient having “upper respiratory illness” or “influenza-like illness”.

6. Symptoms listed above this row were collected by COVID-NET and by FluSurv-NET during all seasons. Other symptoms collected by COVID-NET were: myalgia, chest pain, loss of taste, loss of smell, diarrhea, conjunctivitis, fatigue, headache, rash, nausea/vomiting, abdominal pain, and hemoptysis; for children < 2 years old symptoms also included apnea, cyanosis, decreased vocalization/stridor, dehydration, hypothermia, inability to eat/poor feeding, and lethargy. Other symptoms collected by FluSurv-NET only during the 2017–18 season were: myalgia, chest pain, diarrhea, conjunctivitis, fatigue, headache, nausea/vomiting, and rash. Denominators for percentages for other symptoms for FluSurv-NET for the 2017–2018 season were: for ages 0–4 (N = 1251), ages 5–11 (N = 613), ages 12–17 (N = 308), and ages 0–17 years (N = 2172). No additional symptoms were collected for FluSurv-NET during the 2018–19 or 2019–20 seasons.

1 **Table 2. Underlying medical conditions, interventions, and outcomes of children <18 years old hospitalized with influenza or COVID-19–**

2 **FluSurv-NET<sup>1</sup> and COVID-NET<sup>2</sup>**

	FluSurv-NET			COVID-NET			FluSurv-NET	COVID-NET	<i>P</i> value <sup>6</sup>
	0–4 years	5–11 years	12–17 years	0–4 years	5–11 years	12–17 years	0–17 years	0–17 years	
	(N = 3906)	(N = 2013)	(N = 855)	(N = 1293)	(N = 698)	(N = 1470)	(N = 6774)	(N = 3461)	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
<b>Underlying Medical Conditions</b>									
Any underlying medical condition(s)	1722 (44.1)	1383 (68.7)	669 (78.2)	476 (36.8)	468 (67.0)	913 (62.1)	3774 (55.7)	1857 (53.7)	0.05
Asthma/reactive airway disease	554 (14.2)	723 (35.9)	321 (37.5)	63 (4.9)	161 (23.1)	340 (23.1)	1598 (23.6)	564 (16.3)	<0.01
Chronic lung disease	192 (4.9)	141 (7.0)	72 (8.4)	39 (3.0)	35 (5.0)	41 (2.8)	405 (6.0)	115 (3.3)	<0.01
Chronic metabolic disease	82 (2.1)	93 (4.6)	96 (11.2)	31 (2.4)	46 (6.6)	128 (8.7)	271 (4.0)	205 (5.9)	<0.01
Diabetes mellitus	8 (0.2)	28 (1.4)	45 (5.3)	9 (0.7)	26 (3.7)	97 (6.6)	81 (1.2)	132 (3.8)	<0.01
Blood disorders/hemoglobinopathy	152 (3.9)	153 (7.6)	88 (10.3)	51 (3.9)	68 (9.7)	64 (4.4)	393 (5.8)	183 (5.3)	0.29
Sickle cell disease	103 (2.6)	116 (5.8)	63 (7.4)	33 (2.6)	52 (7.4)	44 (3.0)	282 (4.2)	129 (3.7)	0.29
Cardiovascular disease	289 (7.4)	135 (6.7)	63 (7.4)	133 (10.3)	75 (10.7)	104 (7.1)	487 (7.2)	312 (9.0)	<0.01
Congenital heart disease	186 (4.8)	71 (3.5)	28 (3.3)	69 (5.3)	28 (4.0)	24 (1.6)	285 (4.2)	121 (3.5)	0.08
Neurologic disorder	474 (12.1)	423 (21.0)	211 (24.7)	127 (9.8)	154 (22.1)	207 (14.1)	1108 (16.4)	488 (14.1)	<0.01
Immunocompromised condition	149 (3.8)	187 (9.3)	118 (13.8)	45 (3.5)	62 (8.9)	72 (4.9)	454 (6.7)	179 (5.2)	<0.01
Renal disease	47 (1.2)	57 (2.8)	29 (3.4)	13 (1.0)	12 (1.7)	38 (2.6)	133 (2.0)	63 (1.8)	0.62
Gastrointestinal/liver disease	21 (0.5)	26 (1.3)	14 (1.6)	21 (1.6)	24 (3.4)	30 (2.0)	61 (0.9)	75 (2.2)	<0.01
Obesity <sup>3</sup>	168 (13.6)	304 (18.6)	157 (21.7)	36 (15.1)	167 (30.7)	458 (41.4)	629 (17.5)	661 (35.0)	<0.01
Premature <sup>4</sup>	374 (12.5)	0	0	142 (12.9)	0	0	374 (12.5)	142 (12.9)	0.78
No underlying medical conditions	2184 (55.9)	630 (31.3)	186 (21.8)	817 (63.2)	230 (33.0)	557 (37.9)	3000 (44.3)	1604 (46.3)	0.05
<b>Interventions and Outcomes</b>									
Hospital length of stay (days: median, IQR)	2 (1-3)	2 (1-4)	2 (1-4)	2 (1-4)	3 (2-6)	3 (2-6)	2 (1-4)	3 (2-5)	<0.01
Pneumonia <sup>5</sup>	687 (17.6)	378 (18.8)	143 (16.7)	89 (6.9)	93 (13.3)	279 (19.0)	1208 (17.8)	461 (13.3)	<0.01
ICU admission	810 (20.7)	425 (21.1)	229 (26.8)	304 (23.5)	203 (29.1)	406 (27.6)	1464 (21.6)	913 (26.4)	<0.01
IMV	209 (5.4)	92 (4.6)	55 (6.4)	76 (5.9)	50 (7.2)	90 (6.1)	356 (5.3)	216 (6.2)	0.04
ECMO	14 (0.4)	10 (0.5)	4 (0.5)	4 (0.3)	1 (0.1)	9 (0.6)	28 (0.4)	14 (0.4)	0.95
Died during hospitalization	19 (0.5)	12 (0.6)	6 (0.7)	10 (0.8)	3 (0.4)	12 (0.8)	37 (0.5)	25 (0.7)	0.28

3 FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network; IQR = interquartile range; ICU = intensive  
 4 care unit; IMV = invasive mechanical ventilation; ECMO = extracorporeal membrane oxygenation

1. FluSurv-NET data include the 2017–2018, 2018–2019, and 2019–2020 seasons. Surveillance is conducted during October 1–April 30 each season. The FluSurv-NET catchment area includes California, Colorado, Connecticut, Georgia, Maryland (Baltimore Metropolitan Area), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. Detailed clinical data on hospitalized cases from Maryland were unavailable for the 2019–20 influenza season and were not included.
2. COVID-NET data during October 1, 2020–September 30, 2021 are included. The COVID-NET catchment area includes California, Colorado, Connecticut, Georgia, Iowa, Maryland (entire state), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
3. Obesity status is determined for non-pregnant persons  $\geq 2$  years old by: calculated BMI ( $\geq 95$ th percentile for sex and age), obesity or morbid obesity selected as an underlying medical condition, or ICD-10-CM code E66.0, E66.09, E66.1, E66.8, E66.9, E66.01, E66.2, or Z68.4 entered as a discharge diagnosis. Percentages for obesity are calculated for pediatric cases with non-missing obesity data for FluSurv-NET: ages 2–4 (N = 1233), ages 5–11 (N = 1631), ages 12–17 (N = 723), ages 2–17 years (N = 3587); and for COVID-NET: ages 2–4 (N = 239), ages 5–11 (N = 544), ages 12–17 (N = 1107), ages 2–17 years (N = 1890).
4. Percentages for premature are calculated for children ages 0–2 years for FluSurv-NET (N = 2986) and for COVID-NET (N = 1105).
5. A standardized pneumonia case definition is used, which includes a combination of radiographic findings of bronchopneumonia, air space opacity, consolidation, lobar or interstitial infiltrate within 3 days of hospital admission for FluSurv-NET and at any time during hospitalization for COVID-NET, and either an ICD-10-CM-coded discharge diagnosis of pneumonia or documentation of pneumonia on hospital discharge summary.
6. *P* values are for the comparison of children aged 0–17 years in FluSurv-NET versus COVID-NET



1 **Table 3. Interventions and outcomes among children <18 years old hospitalized with influenza or COVID-19 by symptom status and**  
 2 **reason for admission, FluSurv-NET<sup>1</sup> and COVID-NET<sup>2</sup>**

Interventions and Outcomes	COVID-NET all hospitalizations		COVID-NET ≥1 symptom at admission <sup>3</sup>		COVID-NET admission primarily for COVID-19 <sup>4</sup>		FluSurv-NET all hospitalizations		FluSurv-NET ≥1 symptom at admission <sup>3</sup>	
	n	% (95% CI) <sup>5</sup>	n	% (95% CI) <sup>5</sup>	n	% (95% CI) <sup>5</sup>	n	% (95% CI) <sup>5</sup>	n	% (95% CI) <sup>5</sup>
<b>Ages 0–17</b>	<b>(N = 3461)</b>		<b>(N = 2760)</b>		<b>(N = 2594)</b>		<b>(N = 6774)</b>		<b>(N = 6564)</b>	
Hospital LOS (median, IQR)	3 (2–5)		3 (2–5)		3 (2–5)		2 (1–4)		2 (1–4)	
Pneumonia <sup>6</sup>	461	13.3 (12.2–14.5)	457	16.6 (15.2–18.0)	452	17.4 (16.0–18.9)	1208	17.8 (16.9–18.8)	1200	18.3 (17.4–19.2)
ICU admission	913	26.4 (24.9–27.9)	811	29.4 (27.7–31.1)	781	30.1 (28.3–31.9)	1464	21.6 (20.6–22.6)	1419	21.6 (20.6–22.6)
IMV	216	6.2 (5.5–7.1)	162	5.9 (5.0–6.8)	146	5.6 (4.8–6.6)	356	5.3 (4.7–5.8)	341	5.2 (4.7–5.8)
ECMO	14	0.4 (0.2–0.7)	12	0.4 (0.2–0.8)	12	0.5 (0.2–0.8)	28	0.4 (0.3–0.6)	28	0.4 (0.3–0.6)
Died in Hospital	25	0.7 (0.5–1.1)	18	0.7 (0.4–1.0)	18	0.7 (0.4–1.1)	37	0.5 (0.4–0.8)	35	0.5 (0.4–0.7)
<b>Ages 0–4</b>	<b>(N = 1293)</b>		<b>(N = 1104)</b>		<b>(N = 1106)</b>		<b>(N = 3906)</b>		<b>(N = 3810)</b>	
Hospital LOS (median, IQR)	2 (1–4)		2 (1–4)		2 (1–4)		2 (1–3)		2 (1–3)	
Pneumonia <sup>6</sup>	89	6.9 (5.6–8.4)	88	8.0 (6.4–9.7)	89	8.0 (6.5–9.8)	687	17.6 (16.4–18.8)	684	18.0 (16.7–19.2)
ICU admission	304	23.5 (21.2–25.9)	270	24.5 (21.9–27.1)	269	24.3 (21.8–27.0)	810	20.7 (19.5–22.0)	788	20.7 (19.4–22.0)
IMV	76	5.9 (4.7–7.3)	59	5.3 (4.1–6.8)	58	5.2 (4.0–6.7)	209	5.4 (4.7–6.1)	201	5.3 (4.6–6.0)
ECMO	4	0.3 (0.1–0.8)	3	0.3 (0.1–0.8)	3	0.3 (0.1–0.8)	14	0.4 (0.2–0.6)	14	0.4 (0.2–0.6)
Died in Hospital	10	0.8 (0.4–1.4)	8	0.7 (0.3–1.4)	9	0.8 (0.4–1.5)	19	0.5 (0.3–0.8)	19	0.5 (0.3–0.8)
<b>Ages 5–11</b>	<b>(N = 698)</b>		<b>(N = 596)</b>		<b>(N = 573)</b>		<b>(N = 2013)</b>		<b>(N = 1948)</b>	
Hospital LOS (median, IQR)	3 (2–6)		3 (2–6)		3 (2–6)		2 (1–4)		2 (1–4)	
Pneumonia <sup>6</sup>	93	13.3 (10.9–16.1)	92	15.4 (12.6–18.6)	93	16.2 (13.3–19.5)	378	18.8 (17.1–20.6)	375	19.3 (17.5–21.1)
ICU admission	203	29.1 (25.7–32.6)	193	32.4 (28.6–36.3)	191	33.3 (29.5–37.4)	425	21.1 (19.3–23.0)	408	20.9 (19.2–22.8)
IMV	50	7.2 (5.4–9.3)	39	6.5 (4.7–8.8)	36	6.3 (4.4–8.6)	92	4.6 (3.7–5.6)	89	4.6 (3.7–5.6)
ECMO	1	0.1 (0.0–0.8)	1	0.2 (0.0–0.9)	1	0.2 (0.0–1.0)	10	0.5 (0.2–0.9)	10	0.5 (0.2–0.9)
Died in Hospital	3	0.4 (0.1–1.3)	2	0.3 (0.0–1.2)	1	0.2 (0.0–1.0)	12	0.6 (0.3–1.0)	10	0.5 (0.2–0.9)
<b>Ages 12–17</b>	<b>(N = 1470)</b>		<b>(N = 1060)</b>		<b>(N = 915)</b>		<b>(N = 855)</b>		<b>(N = 806)</b>	
Hospital LOS (median, IQR)	3 (2–6)		3 (2–6)		3 (2–6)		2 (1–4)		2 (1–4)	
Pneumonia <sup>6</sup>	279	19.0 (17.0–21.1)	277	26.1 (23.5–28.9)	270	29.5 (26.6–32.6)	143	16.7 (14.3–19.4)	141	17.5 (14.9–20.3)
ICU admission	406	27.6 (25.3–30.0)	348	32.8 (30.0–35.7)	321	35.1 (32.0–38.3)	229	26.8 (23.8–29.9)	223	27.7 (24.6–30.9)
IMV	90	6.1 (5.0–7.5)	64	6.0 (4.7–7.6)	52	5.7 (4.3–7.4)	55	6.4 (4.9–8.3)	51	6.3 (4.7–8.2)
ECMO	9	0.6 (0.3–1.2)	8	0.8 (0.3–1.5)	8	0.9 (0.4–1.7)	4	0.5 (0.1–1.2)	4	0.5 (0.1–1.3)
Died in Hospital	12	0.8 (0.4–1.4)	8	0.8 (0.3–1.5)	8	0.9 (0.4–1.7)	6	0.7 (0.3–1.5)	6	0.7 (0.3–1.6)

3

1 FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network; LOS = length of stay;  
2 IQR = interquartile range; IMV = invasive mechanical ventilation; ECMO = Extracorporeal Membrane Oxygenation

1. FluSurv-NET data include the 2017–2018, 2018–2019, and 2019–2020 seasons. Surveillance is conducted during October 1–April 30 each season. The FluSurv-NET catchment area includes California, Colorado, Connecticut, Georgia, Maryland (Baltimore Metropolitan Area), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. Detailed clinical data on hospitalized cases from Maryland were unavailable for the 2019–20 influenza season and were not included.

2. COVID-NET data during October 1, 2020–September 30, 2021 are included. The COVID-NET catchment area includes California, Colorado, Connecticut, Georgia, Iowa, Maryland (entire state), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

3. Includes COVID-NET or FluSurv-NET hospitalized patients who had  $\geq 1$  symptom present at hospital admission. The list of symptoms collected varied by surveillance platform and year. Acute respiratory or febrile symptoms were abstracted for all FluSurv-NET seasons and for COVID-NET and are defined as fever, congestion/runny nose, cough, shortness of breath, sore throat, upper respiratory illness or influenza-like illness, and wheezing. Other symptoms abstracted for all FluSurv-NET seasons and for COVID-NET are altered mental state/confusion and seizure. Other symptoms collected by COVID-NET were: myalgia, chest pain, loss of taste, loss of smell, diarrhea, conjunctivitis, fatigue, headache, rash, nausea/vomiting, abdominal pain, and hemoptysis; for children  $<2$  years symptoms also included apnea, cyanosis, decreased vocalization/stridor, dehydration, hypothermia, inability to eat/poor feeding, and lethargy. Other symptoms collected by FluSurv-NET during the 2017–18 season were: myalgia, chest pain, diarrhea, conjunctivitis, fatigue, headache, nausea/vomiting, and rash.

4. Reason for admission is only collected in COVID-NET and includes the following categories: COVID-19 as the primary reason for admission, obstetrics/labor and delivery, inpatient surgery or procedures, psychiatric admission needing acute medical care, trauma, other, or unknown. If the chief complaint or history of present illness documents fever/respiratory illness, COVID-19-like illness, or a suspicion for COVID-19, a case is categorized as having COVID-19 as the primary reason for admission. If the chart specifically indicates that the positive SARS-CoV-2 test was an incidental finding or that the admission was likely not COVID-19-related, the “other, specify” reason for the admission is marked and the admission is noted as “admission likely not COVID-19-related per notes”. For other cases where the “other, specify” reason for admission is marked, an algorithm was developed which incorporates physician review of the free text provided to determine if COVID-19 was likely a primary reason for admission.

5. Exact 95% Confidence Intervals for binomial proportions were calculated using the Clopper-Pearson method

6. A standardized pneumonia case definition is used, which includes a combination of radiographic findings of bronchopneumonia, air space opacity, consolidation, lobar or interstitial infiltrate within 3 days of hospital admission, and either an ICD-10-CM-coded discharge diagnosis of pneumonia or documentation of pneumonia on hospital discharge summary.

3

4 **Figure 1. Counts of COVID-19- and influenza-associated hospitalizations by month among children  $<18$  years old, FluSurv-NET<sup>1</sup> and**  
5 **COVID-NET<sup>2</sup>, October 2017–September 2021**

6

1

2 FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network

1 The 9 influenza-associated hospitalizations reported to FluSurv-NET during October 1, 2020–April 30, 2021 are circled to improve visibility. The FluSurv-NET catchment area includes California, Colorado, Connecticut, Georgia, Iowa (2020–21 season only), Maryland (Baltimore Metropolitan Area), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

2 The COVID-NET catchment area includes California, Colorado, Connecticut, Georgia, Iowa, Maryland (entire state), Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

3 Guidance for slowing the spread of COVID-19 was released on March 16, 2020, after which school closures began. See, e.g., <https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e2.htm>.

3

4

5 **Figure 2. Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children <18 years old, by age group – FluSurv-**  
6 **NET<sup>1</sup> and COVID-NET<sup>2</sup>, 2017–2021**

7 FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network


1 Each season, FluSurv-NET surveillance is conducted from MMWR week 40 (around October 1) of one year to MMWR week 18 (around April 30) of the subsequent year. The grayed-out area on each panel indicates weeks during which FluSurv-NET surveillance was not conducted but COVID-NET surveillance was conducted. FluSurv-NET rate lines were extended beyond week 18 for ease of comparison with COVID-NET rate lines.

2 The COVID-NET surveillance period of October 2020–September 2021 begins at MMWR week 40 of year 2020 and ends at MMWR week 39 of year 2021.

3 MMWR Week 53 for year 2020 is combined with MMWR Week 52 for consistency with other years.

8

1



2

3

4

5

Figure 1  
241x143 mm (0.9 x DPI)




Figure 2  
241x164 mm (0.9 x DPI)

1  
2  
3